P01.116 Treatment with Dabrafenib in a patient with BRAF mutated recurrent ganglioglioma

BACKGROUND: Gangliogliomas are rare tumor usually arising in the supratentorial region, WHO grade 1 or 2. In these tumors, BRAF mutation may constitute a driver genetic alteration and a biomarker of response to BRAF inhibitors. Dabrafenib is an oral inhibitor of BRAF and has shown to significantly i...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Neuro Oncol
Asıl Yazarlar: Pasqualetti, F, Gonnelli, A, Molinari, A, Cantarella, M, Mattioni, R, Baldaccini, D, Grazzini, M, Paiar, F, Rudà, R, Soffietti, R
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2018
Konular:
Poster Presentations
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6144130/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy139.158
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller